位置:首页 > 蛋白库 > CHD2_HUMAN
CHD2_HUMAN
ID   CHD2_HUMAN              Reviewed;        1828 AA.
AC   O14647; C6G482; Q96IP5;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   12-DEC-2006, sequence version 2.
DT   03-AUG-2022, entry version 193.
DE   RecName: Full=Chromodomain-helicase-DNA-binding protein 2;
DE            Short=CHD-2;
DE            EC=3.6.4.12;
DE   AltName: Full=ATP-dependent helicase CHD2;
GN   Name=CHD2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=9326634; DOI=10.1073/pnas.94.21.11472;
RA   Woodage T., Basrai M.A., Baxevanis A.D., Hieter P., Collins F.S.;
RT   "Characterization of the CHD family of proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:11472-11477(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1635-1828 (ISOFORM 1).
RC   TISSUE=T-cell;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-240 AND SER-242, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-207 AND SER-208, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-207; SER-208; THR-240 AND
RP   SER-242, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1365; SER-1386 AND SER-1807,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-207; SER-208; SER-1085 AND
RP   SER-1087, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   VARIANTS DEE94 121-ARG--THR-1828 DEL; ARG-548 AND PRO-823.
RX   PubMed=23708187; DOI=10.1038/ng.2646;
RA   Carvill G.L., Heavin S.B., Yendle S.C., McMahon J.M., O'Roak B.J., Cook J.,
RA   Khan A., Dorschner M.O., Weaver M., Calvert S., Malone S., Wallace G.,
RA   Stanley T., Bye A.M., Bleasel A., Howell K.B., Kivity S., Mackay M.T.,
RA   Rodriguez-Casero V., Webster R., Korczyn A., Afawi Z., Zelnick N.,
RA   Lerman-Sagie T., Lev D., Moeller R.S., Gill D., Andrade D.M., Freeman J.L.,
RA   Sadleir L.G., Shendure J., Berkovic S.F., Scheffer I.E., Mefford H.C.;
RT   "Targeted resequencing in epileptic encephalopathies identifies de novo
RT   mutations in CHD2 and SYNGAP1.";
RL   Nat. Genet. 45:825-830(2013).
RN   [15]
RP   VARIANT DEE94 112-SER--THR-1828 DEL.
RX   PubMed=25356899; DOI=10.1371/journal.pgen.1004772;
RA   Hamdan F.F., Srour M., Capo-Chichi J.M., Daoud H., Nassif C., Patry L.,
RA   Massicotte C., Ambalavanan A., Spiegelman D., Diallo O., Henrion E.,
RA   Dionne-Laporte A., Fougerat A., Pshezhetsky A.V., Venkateswaran S.,
RA   Rouleau G.A., Michaud J.L.;
RT   "De novo mutations in moderate or severe intellectual disability.";
RL   PLoS Genet. 10:E1004772-E1004772(2014).
RN   [16]
RP   VARIANT 178-ARG--THR-1828 DEL.
RX   PubMed=33798445; DOI=10.1016/j.ajhg.2021.03.013;
RA   Courage C., Oliver K.L., Park E.J., Cameron J.M., Grabinska K.A., Muona M.,
RA   Canafoglia L., Gambardella A., Said E., Afawi Z., Baykan B., Brandt C.,
RA   di Bonaventura C., Chew H.B., Criscuolo C., Dibbens L.M., Castellotti B.,
RA   Riguzzi P., Labate A., Filla A., Giallonardo A.T., Berecki G.,
RA   Jackson C.B., Joensuu T., Damiano J.A., Kivity S., Korczyn A., Palotie A.,
RA   Striano P., Uccellini D., Giuliano L., Andermann E., Scheffer I.E.,
RA   Michelucci R., Bahlo M., Franceschetti S., Sessa W.C., Berkovic S.F.,
RA   Lehesjoki A.E.;
RT   "Progressive myoclonus epilepsies-Residual unsolved cases have marked
RT   genetic heterogeneity including dolichol-dependent protein glycosylation
RT   pathway genes.";
RL   Am. J. Hum. Genet. 108:722-738(2021).
CC   -!- FUNCTION: DNA-binding helicase that specifically binds to the promoter
CC       of target genes, leading to chromatin remodeling, possibly by promoting
CC       deposition of histone H3.3. Involved in myogenesis via interaction with
CC       MYOD1: binds to myogenic gene regulatory sequences and mediates
CC       incorporation of histone H3.3 prior to the onset of myogenic gene
CC       expression, promoting their expression (By similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + H(+) + phosphate; Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.12;
CC   -!- SUBUNIT: Interacts with MYOD1. Interacts with histone H3.3 (By
CC       similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       O14647; Q8N7W2-2: BEND7; NbExp=3; IntAct=EBI-1210503, EBI-10181188;
CC       O14647; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-1210503, EBI-10172526;
CC       O14647; Q969V4: TEKT1; NbExp=3; IntAct=EBI-1210503, EBI-10180409;
CC       O14647; Q9NVV9: THAP1; NbExp=3; IntAct=EBI-1210503, EBI-741515;
CC       O14647; Q8WV44: TRIM41; NbExp=4; IntAct=EBI-1210503, EBI-725997;
CC       O14647-3; Q8IYF1: ELOA2; NbExp=3; IntAct=EBI-11985957, EBI-741705;
CC       O14647-3; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-11985957, EBI-16439278;
CC       O14647-3; Q9BYV2: TRIM54; NbExp=3; IntAct=EBI-11985957, EBI-2130429;
CC       O14647-3; Q8TD17: ZNF398; NbExp=3; IntAct=EBI-11985957, EBI-8643207;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. Note=Binds to myogenic
CC       gene promoters. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O14647-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O14647-2; Sequence=VSP_021918, VSP_021919;
CC       Name=3;
CC         IsoId=O14647-3; Sequence=VSP_042791;
CC   -!- DISEASE: Developmental and epileptic encephalopathy 94 (DEE94)
CC       [MIM:615369]: A form of epileptic encephalopathy, a heterogeneous group
CC       of early-onset epilepsies characterized by refractory seizures,
CC       neurodevelopmental impairment, and poor prognosis. Development is
CC       normal prior to seizure onset, after which cognitive and motor delays
CC       become apparent. DEE94 is an autosomal dominant, severe form
CC       characterized by onset of multiple seizure types in the first few years
CC       of life. {ECO:0000269|PubMed:23708187, ECO:0000269|PubMed:25356899}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the SNF2/RAD54 helicase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF006514; AAB87382.1; -; mRNA.
DR   EMBL; BT007050; AAP35699.1; -; mRNA.
DR   EMBL; FJ515838; ACS13730.1; -; Genomic_DNA.
DR   EMBL; AC013394; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471101; EAX02160.1; -; Genomic_DNA.
DR   EMBL; BC007347; AAH07347.1; -; mRNA.
DR   EMBL; CR978407; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS10374.2; -. [O14647-1]
DR   CCDS; CCDS45356.1; -. [O14647-3]
DR   RefSeq; NP_001036037.1; NM_001042572.2. [O14647-3]
DR   RefSeq; NP_001262.3; NM_001271.3. [O14647-1]
DR   AlphaFoldDB; O14647; -.
DR   SMR; O14647; -.
DR   BioGRID; 107531; 48.
DR   IntAct; O14647; 26.
DR   MINT; O14647; -.
DR   STRING; 9606.ENSP00000377747; -.
DR   iPTMnet; O14647; -.
DR   PhosphoSitePlus; O14647; -.
DR   SwissPalm; O14647; -.
DR   BioMuta; CHD2; -.
DR   EPD; O14647; -.
DR   jPOST; O14647; -.
DR   MassIVE; O14647; -.
DR   MaxQB; O14647; -.
DR   PaxDb; O14647; -.
DR   PeptideAtlas; O14647; -.
DR   PRIDE; O14647; -.
DR   ProteomicsDB; 48144; -. [O14647-1]
DR   ProteomicsDB; 48145; -. [O14647-2]
DR   ProteomicsDB; 48146; -. [O14647-3]
DR   ABCD; O14647; 1 sequenced antibody.
DR   Antibodypedia; 29044; 208 antibodies from 34 providers.
DR   DNASU; 1106; -.
DR   Ensembl; ENST00000394196.9; ENSP00000377747.4; ENSG00000173575.22. [O14647-1]
DR   Ensembl; ENST00000420239.7; ENSP00000406581.2; ENSG00000173575.22. [O14647-3]
DR   Ensembl; ENST00000626874.2; ENSP00000486629.1; ENSG00000173575.22. [O14647-2]
DR   GeneID; 1106; -.
DR   KEGG; hsa:1106; -.
DR   MANE-Select; ENST00000394196.9; ENSP00000377747.4; NM_001271.4; NP_001262.3.
DR   UCSC; uc002bsn.4; human. [O14647-1]
DR   CTD; 1106; -.
DR   DisGeNET; 1106; -.
DR   GeneCards; CHD2; -.
DR   GeneReviews; CHD2; -.
DR   HGNC; HGNC:1917; CHD2.
DR   HPA; ENSG00000173575; Low tissue specificity.
DR   MalaCards; CHD2; -.
DR   MIM; 602119; gene.
DR   MIM; 615369; phenotype.
DR   neXtProt; NX_O14647; -.
DR   OpenTargets; ENSG00000173575; -.
DR   Orphanet; 2382; Lennox-Gastaut syndrome.
DR   Orphanet; 1942; Myoclonic-astatic epilepsy.
DR   PharmGKB; PA26453; -.
DR   VEuPathDB; HostDB:ENSG00000173575; -.
DR   eggNOG; KOG0384; Eukaryota.
DR   GeneTree; ENSGT00940000155888; -.
DR   HOGENOM; CLU_645515_0_0_1; -.
DR   InParanoid; O14647; -.
DR   OMA; CDTFNNW; -.
DR   OrthoDB; 57339at2759; -.
DR   PhylomeDB; O14647; -.
DR   TreeFam; TF313461; -.
DR   PathwayCommons; O14647; -.
DR   SignaLink; O14647; -.
DR   SIGNOR; O14647; -.
DR   BioGRID-ORCS; 1106; 29 hits in 1093 CRISPR screens.
DR   ChiTaRS; CHD2; human.
DR   GeneWiki; CHD2; -.
DR   GenomeRNAi; 1106; -.
DR   Pharos; O14647; Tbio.
DR   PRO; PR:O14647; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; O14647; protein.
DR   Bgee; ENSG00000173575; Expressed in calcaneal tendon and 177 other tissues.
DR   ExpressionAtlas; O14647; baseline and differential.
DR   Genevisible; O14647; HS.
DR   GO; GO:0000785; C:chromatin; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IBA:GO_Central.
DR   GO; GO:0140658; F:ATP-dependent chromatin remodeler activity; IBA:GO_Central.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0003677; F:DNA binding; IBA:GO_Central.
DR   GO; GO:0003678; F:DNA helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0042393; F:histone binding; ISS:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IEA:Ensembl.
DR   GO; GO:0006338; P:chromatin remodeling; IBA:GO_Central.
DR   GO; GO:0010467; P:gene expression; IEA:Ensembl.
DR   GO; GO:0060218; P:hematopoietic stem cell differentiation; IEA:Ensembl.
DR   GO; GO:0007517; P:muscle organ development; ISS:UniProtKB.
DR   GO; GO:0034728; P:nucleosome organization; IBA:GO_Central.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   Gene3D; 3.40.50.10810; -; 1.
DR   Gene3D; 3.40.50.300; -; 1.
DR   InterPro; IPR040793; CDH1_2_SANT_HL1.
DR   InterPro; IPR016197; Chromo-like_dom_sf.
DR   InterPro; IPR000953; Chromo/chromo_shadow_dom.
DR   InterPro; IPR023780; Chromo_domain.
DR   InterPro; IPR023779; Chromodomain_CS.
DR   InterPro; IPR025260; DUF4208.
DR   InterPro; IPR014001; Helicase_ATP-bd.
DR   InterPro; IPR001650; Helicase_C.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR038718; SNF2-like_sf.
DR   InterPro; IPR000330; SNF2_N.
DR   Pfam; PF18375; CDH1_2_SANT_HL1; 1.
DR   Pfam; PF00385; Chromo; 2.
DR   Pfam; PF13907; DUF4208; 1.
DR   Pfam; PF00271; Helicase_C; 1.
DR   Pfam; PF00176; SNF2-rel_dom; 1.
DR   SMART; SM00298; CHROMO; 2.
DR   SMART; SM00487; DEXDc; 1.
DR   SMART; SM01176; DUF4208; 1.
DR   SMART; SM00490; HELICc; 1.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   SUPFAM; SSF54160; SSF54160; 2.
DR   PROSITE; PS00598; CHROMO_1; 2.
DR   PROSITE; PS50013; CHROMO_2; 2.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Chromatin regulator; Disease variant;
KW   DNA-binding; Epilepsy; Helicase; Hydrolase; Myogenesis; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Reference proteome; Repeat; Transcription;
KW   Transcription regulation.
FT   CHAIN           1..1828
FT                   /note="Chromodomain-helicase-DNA-binding protein 2"
FT                   /id="PRO_0000080226"
FT   DOMAIN          261..353
FT                   /note="Chromo 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00053"
FT   DOMAIN          378..456
FT                   /note="Chromo 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00053"
FT   DOMAIN          496..666
FT                   /note="Helicase ATP-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   DOMAIN          795..946
FT                   /note="Helicase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00542"
FT   REGION          1..243
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1030..1124
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1331..1462
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1556..1638
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1680..1828
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           617..620
FT                   /note="DEAH box"
FT   COMPBIAS        14..75
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        83..123
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        124..138
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        139..159
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        177..200
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        216..235
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1030..1069
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1079..1124
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1350..1435
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1556..1577
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1586..1604
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1622..1638
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1700..1749
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1798..1813
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1814..1828
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         509..516
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   MOD_RES         207
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569"
FT   MOD_RES         208
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569"
FT   MOD_RES         240
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         242
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         1085
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1087
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1365
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1386
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1807
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         502..1828
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.2"
FT                   /id="VSP_042791"
FT   VAR_SEQ         1719..1739
FT                   /note="HHHDSKRRRSDEFRPQNYHQQ -> YAKGCETPGANLCQELFLGRK (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9326634"
FT                   /id="VSP_021918"
FT   VAR_SEQ         1740..1828
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9326634"
FT                   /id="VSP_021919"
FT   VARIANT         112..1828
FT                   /note="Missing (in DEE94)"
FT                   /evidence="ECO:0000269|PubMed:25356899"
FT                   /id="VAR_078614"
FT   VARIANT         121..1828
FT                   /note="Missing (in DEE94)"
FT                   /evidence="ECO:0000269|PubMed:23708187"
FT                   /id="VAR_078615"
FT   VARIANT         178..1828
FT                   /note="Missing (found in a patient with progressive
FT                   myoclonus epilepsy; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:33798445"
FT                   /id="VAR_085039"
FT   VARIANT         548
FT                   /note="W -> R (in DEE94; dbSNP:rs864309537)"
FT                   /evidence="ECO:0000269|PubMed:23708187"
FT                   /id="VAR_070209"
FT   VARIANT         823
FT                   /note="L -> P (in DEE94; dbSNP:rs864309540)"
FT                   /evidence="ECO:0000269|PubMed:23708187"
FT                   /id="VAR_070210"
FT   VARIANT         1574
FT                   /note="G -> A (in dbSNP:rs56227200)"
FT                   /id="VAR_061099"
FT   CONFLICT        1156
FT                   /note="I -> L (in Ref. 1; AAB87382)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1828 AA;  211344 MW;  13139D6059210F00 CRC64;
     MMRNKDKSQE EDSSLHSNAS SHSASEEASG SDSGSQSESE QGSDPGSGHG SESNSSSESS
     ESQSESESES AGSKSQPVLP EAKEKPASKK ERIADVKKMW EEYPDVYGVR RSNRSRQEPS
     RFNIKEEASS GSESGSPKRR GQRQLKKQEK WKQEPSEDEQ EQGTSAESEP EQKKVKARRP
     VPRRTVPKPR VKKQPKTQRG KRKKQDSSDE DDDDDEAPKR QTRRRAAKNV SYKEDDDFET
     DSDDLIEMTG EGVDEQQDNS ETIEKVLDSR LGKKGATGAS TTVYAIEANG DPSGDFDTEK
     DEGEIQYLIK WKGWSYIHST WESEESLQQQ KVKGLKKLEN FKKKEDEIKQ WLGKVSPEDV
     EYFNCQQELA SELNKQYQIV ERVIAVKTSK STLGQTDFPA HSRKPAPSNE PEYLCKWMGL
     PYSECSWEDE ALIGKKFQNC IDSFHSRNNS KTIPTRECKA LKQRPRFVAL KKQPAYLGGE
     NLELRDYQLE GLNWLAHSWC KNNSVILADE MGLGKTIQTI SFLSYLFHQH QLYGPFLIVV
     PLSTLTSWQR EFEIWAPEIN VVVYIGDLMS RNTIREYEWI HSQTKRLKFN ALITTYEILL
     KDKTVLGSIN WAFLGVDEAH RLKNDDSLLY KTLIDFKSNH RLLITGTPLQ NSLKELWSLL
     HFIMPEKFEF WEDFEEDHGK GRENGYQSLH KVLEPFLLRR VKKDVEKSLP AKVEQILRVE
     MSALQKQYYK WILTRNYKAL AKGTRGSTSG FLNIVMELKK CCNHCYLIKP PEENERENGQ
     EILLSLIRSS GKLILLDKLL TRLRERGNRV LIFSQMVRML DILAEYLTIK HYPFQRLDGS
     IKGEIRKQAL DHFNADGSED FCFLLSTRAG GLGINLASAD TVVIFDSDWN PQNDLQAQAR
     AHRIGQKKQV NIYRLVTKGT VEEEIIERAK KKMVLDHLVI QRMDTTGRTI LENNSGRSNS
     NPFNKEELTA ILKFGAEDLF KELEGEESEP QEMDIDEILR LAETRENEVS TSATDELLSQ
     FKVANFATME DEEELEERPH KDWDEIIPEE QRKKVEEEER QKELEEIYML PRIRSSTKKA
     QTNDSDSDTE SKRQAQRSSA SESETEDSDD DKKPKRRGRP RSVRKDLVEG FTDAEIRRFI
     KAYKKFGLPL ERLECIARDA ELVDKSVADL KRLGELIHNS CVSAMQEYEE QLKENASEGK
     GPGKRRGPTI KISGVQVNVK SIIQHEEEFE MLHKSIPVDP EEKKKYCLTC RVKAAHFDVE
     WGVEDDSRLL LGIYEHGYGN WELIKTDPEL KLTDKILPVE TDKKPQGKQL QTRADYLLKL
     LRKGLEKKGA VTGGEEAKLK KRKPRVKKEN KVPRLKEEHG IELSSPRHSD NPSEEGEVKD
     DGLEKSPMKK KQKKKENKEN KEKQMSSRKD KEGDKERKKS KDKKEKPKSG DAKSSSKSKR
     SQGPVHITAG SEPVPIGEDE DDDLDQETFS ICKERMRPVK KALKQLDKPD KGLNVQEQLE
     HTRNCLLKIG DRIAECLKAY SDQEHIKLWR RNLWIFVSKF TEFDARKLHK LYKMAHKKRS
     QEEEEQKKKD DVTGGKKPFR PEASGSSRDS LISQSHTSHN LHPQKPHLPA SHGPQMHGHP
     RDNYNHPNKR HFSNADRGDW QRERKFNYGG GNNNPPWGSD RHHQYEQHWY KDHHYGDRRH
     MDAHRSGSYR PNNMSRKRPY DQYSSDRDHR GHRDYYDRHH HDSKRRRSDE FRPQNYHQQD
     FRRMSDHRPA MGYHGQGPSD HYRSFHTDKL GEYKQPLPPL HPAVSDPRSP PSQKSPHDSK
     SPLDHRSPLE RSLEQKNNPD YNWNVRKT
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024